UnknownNot Applicable

HVNI Versus NIV In Management Of Acute Hypercapnic Respiratory Failure In OHS

56 participantsStarted 2023-05-01

Plain-language summary

1. Assessment of benefits of HVNI in management of obesity hypoventilation syndrome complicated with acute hypercapnic respiratory failure. 2. Compare the value, safety and effectiveness of HVNI and NIV in patients with obesity hypoventilation syndrome complicated with acute hypercapnic respiratory failure.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \>18 years.
✓. Obesity hypoventilation syndrome with acute hypercapnic respiratory failure. A) Body mass index \[BMI\] ≥ 30 kg/m2. B) Daytime hypercapnia (PaCO2 \> 45 mm Hg) C) PH \< 7.35 D) Arterial oxygen saturation (SaO2) \<90%

Exclusion criteria

✕. Age \<18 years.
✕. Pulmonary infiltrates suggesting pulmonary edema, pneumonia, active tuberculosis, or its sequelae.
✕. Patients with gas exchange alterations due to other conditions, such as bronchiectasis, fibrosis of the pleural space (fibrothorax), neuromuscular disease and chronic obstructive pulmonary disease (COPD)
✕. Pregnancy.
✕. Contraindications for positive-airway pressure devices.

What they're measuring

Improvement of hypercapnia and oxygenation

Timeframe: Baseline

Trial details

NCT IDNCT05805293

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-01

Contact for this trial

Rofaida Raafat Ibrahim, Assistant lecturer

01062023404 rofaidaraafatchest@gmail.com

View on ClinicalTrials.gov More Obesity Hypoventilation Syndrome (OHS) trials